CD22 and acute lymphoblastic leukemia: One approach to overcoming antigen loss following CAR T cell therapy is to simultaneously target more than one antigen on cancer cells, an approach that is compelling for B-ALL, given that anti-CD22 CAR T cells have also demonstrated clinical efficacy [11].